GNPX - Genprex, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.41
-0.03 (-1.23%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.44
Open2.45
Bid2.40 x 800
Ask2.50 x 900
Day's Range2.40 - 2.45
52 Week Range2.16 - 19.45
Volume28,075
Avg. Volume79,045
Market Cap36.322M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.67
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wirelast month

    Genprex to Present at Upcoming Investor Conferences

    Genprex, Inc. , a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today

  • Business Wirelast month

    Genprex Provides Clinical and Corporate Update for Second Quarter 2018

    Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the second quarter ended June 30, 2018 on Form 10-Q with the Securities and Exchange Commission. Rodney Varner, Chairman and CEO, remarked, “We have made significant progress in recent months to advance the development of Oncoprex™ for treatment of non-small cell lung cancer (NSCLC), including engaging collaborators with expertise and other resources necessary for important pre-clinical and clinical services.

  • Business Wire2 months ago

    Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer

    Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it has amended its agreement with The University of Texas MD Anderson Cancer Center to resume patient enrollment in its Phase I/II clinical trial evaluating the combination of the company’s investigational drug Oncoprex™ and erlotinib (Tarceva®) for the treatment of Stage IV non-small cell lung cancer (NSCLC). Oncoprex is a TUSC2 gene encapsulated in a positively charged nanovesicle made from lipid molecules and injected intravenously, which can specifically target cancer cells and insert wild-type TUSC2 into cellular DNA, effectively increasing expression of the TUSC2 protein and promoting tumor cell death.

  • Business Wire2 months ago

    Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies

    Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has entered a Sponsored Research Agreement (“Agreement”) with The University of Texas MD Anderson Cancer Center under which Genprex will sponsor a pre-clinical study, entitled “A Novel Therapeutic Approach for the Treatment of Cancer Using a Combination of the Multifactorial Tumor Suppressor Gene TUSC2 and Immunotherapy,” to be conducted under the direction of Jack A. Roth, MD, FACS. TUSC2 is the active agent in Genprex’s investigational drug candidate Oncoprex™.

  • Genprex To Present At The Singular Research Summer Solstice 2018 Conference
    PR Newswire2 months ago

    Genprex To Present At The Singular Research Summer Solstice 2018 Conference

    NEW YORK , July 18, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, ...

  • GlobeNewswire3 months ago

    Diamond Equity Research Initiates Coverage on Genprex Inc. (NASDAQ: GNPX) with a Valuation of $13 Per Share

    NEW YORK, July 02, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies has initiated coverage of Genprex Inc. (GNPX). The in-depth 27-page initiation report includes detailed information on Genprex 's business model, services, industry, valuation, management, and risks. The full research report is available here.

  • Genprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program
    PR Newswire3 months ago

    Genprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program

    AUSTIN, Texas AND CAMBRIDGE, Mass., June 26, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected 4Clinics Group Sprl to provide support for the clinical development of the Company's lead drug candidate, Oncoprex™, for the treatment of non-small cell lung cancer (NSCLC). "This is an important step forward for Genprex as we expand the scope of the Oncoprex clinical development program to build on the encouraging data we've compiled to date," said Julien Pham, MD, MPH, President and Chief Operating Officer of Genprex. 4Clinics is a global contract research organization that provides comprehensive clinical expertise to clients across data management, biostatistics, statistical programming, scientific writing, regulatory affairs and clinical operations services for clinical, observational and epidemiological studies.

  • Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program
    PR Newswire4 months ago

    Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program

    AUSTIN, Texas, May 31, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it entered into a Master Services Agreement with WIRB-Copernicus Group, Inc. ("WCG"), through which WCG will serve as the Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) of record for new clinical trial sites that Genprex anticipates adding to participate in its  Phase I/II clinical trial of lead product candidate, OncoprexTM, in combination with erlotinib (Tarceva®) in non-small cell lung cancer.

  • Genprex (Nasdaq: GNPX) To Ring The Nasdaq Stock Market Closing Bell
    PR Newswire4 months ago

    Genprex (Nasdaq: GNPX) To Ring The Nasdaq Stock Market Closing Bell

    AUSTIN, Texas , May 29, 2018 /PRNewswire/ --   Genprex, Inc. (Nasdaq: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology ...

  • Genprex To Present At Upcoming Investor And Industry Conferences
    PR Newswire4 months ago

    Genprex To Present At Upcoming Investor And Industry Conferences

    AUSTIN, Texas and CAMBRIDGE, Mass. , May 23, 2018 /PRNewswire/ --   Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary ...

  • Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program
    PR Newswire5 months ago

    Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program

    AUSTIN, Texas and CAMBRIDGE, Mass., May 8, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected Accenture to provide clinical data management services to help accelerate the clinical development of Genprex's lead drug candidate, Oncoprex™, for the treatment of non-small cell lung cancer (NSCLC). Under the agreement, Accenture, a leading global professional services company, is supporting Genprex with clinical data management and submission-compliant CDISC deliverable activities for the Phase I/II clinical trial combining Genprex's Oncoprex and the EGFR-inhibitor erlotinib (Tarceva®) in stage IV lung cancer.  Accenture's Clinical Data Management team has executed thousands of clinical trials in a variety of therapeutic areas, supported by experienced industry professionals who understand the importance of a standards-fueled, data-centric approach across each phase of drug development.

  • Genprex To Present At 2018 Disruptive Growth & Healthcare Conference
    PR Newswire5 months ago

    Genprex To Present At 2018 Disruptive Growth & Healthcare Conference

    AUSTIN, Texas , May 7, 2018 /PRNewswire/ --  Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, ...

  • Genprex Announces $10 Million Private Placement
    PR Newswire5 months ago

    Genprex Announces $10 Million Private Placement

    AUSTIN, Texas, May 7, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into definitive securities purchase agreements with institutional investors in connection with a private placement of $10.0 million of shares of its common stock and warrants. The per share purchase price of the common stock is equal to $12.07, and the initial exercise price for the warrants is equal to $15.62 per share. The warrants will be exercisable on the earlier of 6 months from the issuance date or the date of effectiveness of the registration statement registering the underlying shares for resale and will expire 5 years from such date.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Genprex and Celgene

    Genprex also announced this week that it has established offices in Massachusetts to help accelerate the clinical development of Oncoprex, its lead immunogene therapy for non-small cell lung cancer. Shares of Celgene also saw gains after a report discussed that Juno Therapeutics' CEO quietly stepped down from his role and joined Celgene's board. The company also announced on Wednesday that it has established offices in Cambridge, Mass. to help accelerate the clinical development of its lead drug candidate, Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC).

  • ACCESSWIRE5 months ago

    Genprex, New IPO in Biotech Generates Investor Interest with Lung Cancer Program

    NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Genprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences
    PR Newswire5 months ago

    Genprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences

    AUSTIN, Texas, April 18, 2018 /PRNewswire/ -- Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that it has entered an agreement with The University of Texas at Austin Dell Medical School to establish executive offices at the school's Health Discovery Building, joining the WorkSpaces @ Texas Health CoLab that brings together value-focused health entrepreneurs and businesses to enable a robust health innovation ecosystem. "Texas Health CoLab combines world-class research and technology capabilities, along with passionate people and space for multi-disciplinary teamwork, and we're delighted to welcome Genprex to our collaborative space," said Dr. Ruben Rathnasingham, Managing Director of the Texas Health CoLab.

  • Genprex Provides Clinical and Corporate Update
    PR Newswire5 months ago

    Genprex Provides Clinical and Corporate Update

    Announced in January 2017 positive interim data from the Phase II portion of the ongoing Phase I/II clinical trial evaluating OncoprexTM in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®) for the treatment of late stage non-small cell lung cancer (NSCLC) patients, with and without EGFR mutations, who have failed at least two drug regimens.  Of the 39 patients allowed in the protocol for the Phase II portion of the trial, 10 have been enrolled and nine are evaluable under the trial protocol as they received two or more cycles of the treatment.

  • Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy
    PR Newswire5 months ago

    Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy

    AUSTIN, Texas and CAMBRIDGE, Mass., April 11, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Julien L. Pham, MD, MPH as the Company's President. In this expanded senior management position, Dr. Pham, who joined Genprex in 2016 as Chief Operating Officer, will lead the Company's clinical development program as well as establish and grow strategic partnerships that contribute to Genprex's corporate objectives and innovative work across oncology and gene therapy.

  • ACCESSWIRE5 months ago

    Genprex (GNPX) Stock: May Offer Significant Growth Opportunity

    This Research Originally Appeared on CNA Finance CORAL SPRINGS, FL / ACCESSWIRE / April 10, 2018 / Genprex, Inc. closed its IPO on April 3, 2018, selling 1.28 million shares of common stock at a price ...

  • Genprex Announces Pricing of Initial Public Offering of Common Stock
    PR Newswire6 months ago

    Genprex Announces Pricing of Initial Public Offering of Common Stock

    AUSTIN, Texas , March 29, 2018 /PRNewswire/ -- Genprex, Inc. , a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the pricing of its initial ...